跳到主要内容
  • Sign in
    Welcome !
    My account
    Logout

REGENXBIO Inc. (RGNX) Stock Forecast 2025 - AI Price Prediction & Analysis

REGENXBIO Inc. (RGNX) AI Stock Price Forecast & Investment Analysis

REGENXBIO Inc. Stock Price Chart and Technical Analysis

Loading REGENXBIO Inc. interactive price chart and technical analysis...

REGENXBIO Inc. (RGNX) - Comprehensive Stock Analysis & Investment Research

Deep dive into REGENXBIO Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about REGENXBIO Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For REGENXBIO Inc.: REGENXBIO Inc. operates in the Life Sciences sector, making it an emerging small-cap investment.

REGENXBIO Inc. (Stock Symbol: RGNX) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry.

The organization employs approximately 408 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing REGENXBIO Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For REGENXBIO Inc.: With $155M in annual revenue and -180.4% net margin, the company demonstrates developing profitability.

Annual Revenue: $155 million generating a -180.4% net profit margin .

Market Capitalization: $499 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): 16.3% - Excellent shareholder return efficiency, indicating strong management effectiveness.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for REGENXBIO Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For REGENXBIO Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for REGENXBIO Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: REGENXBIO Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For REGENXBIO Inc.: Strong free cash flow generation demonstrates solid operational efficiency.

REGENXBIO Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company demonstrates robust operational efficiency through strong free cash flow generation of $143 million annually.

The company maintains a healthy 16.4% gross margin, indicating strong pricing power and operational efficiency.

REGENXBIO Inc. (RGNX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for REGENXBIO Inc. stock analysis.

Loading REGENXBIO Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into REGENXBIO Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if REGENXBIO Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For REGENXBIO Inc.: With a P/E ratio of -1.81, the market sees the stock as potentially undervalued.

P/E Ratio -1.81x
P/B Ratio 2.34x
Market Cap $499M
EPS $-3.44
Book Value/Share $4.15
Revenue/Share $3.03
FCF/Share $-3.61
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently REGENXBIO Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For REGENXBIO Inc.: An ROE of 16.3% demonstrates excellent shareholder value creation.

ROE 16.3%
ROA 10.6%
ROIC 17.5%
Gross Margin 16.4%
Operating Margin -185.7%
Net Margin -180.4%
EBT Margin 24.2%
Tax Rate 11.7%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess REGENXBIO Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For REGENXBIO Inc.: A current ratio of 3.73 indicates strong liquidity.

Current Ratio 3.73x
Quick Ratio 3.51x
D/E Ratio 0.12x
Financial Leverage 1.49x
Interest Coverage 5.5x
Working Capital $450M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal REGENXBIO Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For REGENXBIO Inc.: Free cash flow of $143M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $207M
Free Cash Flow $143M
Capital Spending $-64M
FCF/Sales 30.2%
CapEx/Sales 13.5%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively REGENXBIO Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For REGENXBIO Inc.: An asset turnover of 0.50x suggests room for improvement in asset utilization.

Asset Turnover 0.50x
Receivables Turnover 30.5x
Fixed Assets Turnover 2.7x
Days Sales Outstanding 12 days
Payables Period 105 days
Understanding Financial Statement Data

What these metrics mean: Key figures from REGENXBIO Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For REGENXBIO Inc.: With annual revenue of $155M, REGENXBIO Inc. demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $155M
R&D Expense $214M
SG&A Expense $18M
Cost of Goods Sold $38M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 44%
Cash & Short-term Investments 38%
Total Liabilities 33%
Short-term Debt 69%
Accounts Receivable 3%
Dividend & Shareholder Information
Shares Outstanding 51M
Growth Metrics (YoY)
EPS Growth -68.8%

Latest REGENXBIO Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting REGENXBIO Inc. (RGNX) stock price and investment outlook.

, source: Yahoo Finance

We feel now is a pretty good time to analyse REGENXBIO Inc.'s (NASDAQ:RGNX) business as it appears the company may be on the cusp of a considerable accomplishment. REGENXBIO Inc., a clinical-stage ...

, source: Nasdaq

Over 6,000 diseases are caused by abnormal genes, and innovation such as gene sequencing has unleashed a torrent of research into gene therapies designed to fix these abnormalities. The potential to ...

, source: Nasdaq

Fintel reports that GIC Private has filed a 13G form with the SEC disclosing ownership of 2.20MM shares of Regenxbio Inc (RGNX). This represents 5.1% of the company. In their previous filing dated ...

, source: Seeking Alpha

Good day, and thank you for standing by. Welcome to the REGENXBIO Inc. First Quarter 2023 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would ...

REGENXBIO Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of REGENXBIO Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS Unlock Forecast - 30 Days FREE Trial $85M -1.9x 0.7x
ABP Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
ABPWW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
ACLX Unlock Forecast - 30 Days FREE Trial $3725M -74.1x 8.9x
ACOG Unlock Forecast - 30 Days FREE Trial $143M x 4.5x
ADAP Unlock Forecast - 30 Days FREE Trial $65M -13.2x -11.8x
ADMA Unlock Forecast - 30 Days FREE Trial $3873M 18.5x 9.7x
ADPT Unlock Forecast - 30 Days FREE Trial $2067M -4.6x 11.5x
ADVM Unlock Forecast - 30 Days FREE Trial $58M -1.8x 2.2x
AGEN Unlock Forecast - 30 Days FREE Trial $130M -0.5x -0.5x
AIM Unlock Forecast - 30 Days FREE Trial $2M -0.5x -183.3x
AIMI Unlock Forecast - 30 Days FREE Trial $2M x x
ALEC Unlock Forecast - 30 Days FREE Trial $305M -1.2x 4.3x
ALGS Unlock Forecast - 30 Days FREE Trial $107M -19.2x 1.1x
ALLO Unlock Forecast - 30 Days FREE Trial $253M -1.4x 0.7x
ALVR Unlock Forecast - 30 Days FREE Trial $49M -0.5x 0.4x
AMGN Unlock Forecast - 30 Days FREE Trial $152957M 23.1x 20.6x
APGE Unlock Forecast - 30 Days FREE Trial $2195M -20.5x 4.3x
APTO Unlock Forecast - 30 Days FREE Trial $6M 0.0x -1.3x
APTOF Unlock Forecast - 30 Days FREE Trial $3M x x
ARMP Unlock Forecast - 30 Days FREE Trial $103M -1.0x -1.6x
ARTV Unlock Forecast - 30 Days FREE Trial $88M x 0.6x
ATHA Unlock Forecast - 30 Days FREE Trial $15M -0.2x 0.5x
ATRA Unlock Forecast - 30 Days FREE Trial $149M 25.8x -1.1x
ATYR Unlock Forecast - 30 Days FREE Trial $515M -3.6x 6.9x
AURA Unlock Forecast - 30 Days FREE Trial $402M -4.9x 2.3x
AUTL Unlock Forecast - 30 Days FREE Trial $389M x 1.1x
AVXL Unlock Forecast - 30 Days FREE Trial $758M -17.3x 8.3x
BCAB Unlock Forecast - 30 Days FREE Trial $125M -1.1x 1.0x
BCDA Unlock Forecast - 30 Days FREE Trial $12M -0.6x -7.8x
BCLI Unlock Forecast - 30 Days FREE Trial $7M -4.9x -0.9x
BCRX Unlock Forecast - 30 Days FREE Trial $1802M -12.1x -4.0x
BDTX Unlock Forecast - 30 Days FREE Trial $171M 11.8x 1.3x
BEAM Unlock Forecast - 30 Days FREE Trial $2115M -12.6x 2.0x
BIIB Unlock Forecast - 30 Days FREE Trial $18125M 12.8x 1.5x
BKHA Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
BKHAU Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
BLUE Unlock Forecast - 30 Days FREE Trial $49M -0.2x -0.8x
CABA Unlock Forecast - 30 Days FREE Trial $155M -1.6x 0.9x
CADL Unlock Forecast - 30 Days FREE Trial $338M -4.6x 4.5x
CCCC Unlock Forecast - 30 Days FREE Trial $193M -2.6x 1.1x
CDTX Unlock Forecast - 30 Days FREE Trial $728M -1.0x 5.1x
CELZ Unlock Forecast - 30 Days FREE Trial $9M -3.4x 1.3x
CERO Unlock Forecast - 30 Days FREE Trial $2M x -196.2x
CEROW Unlock Forecast - 30 Days FREE Trial $2M x -0.5x
CGEM Unlock Forecast - 30 Days FREE Trial $449M -4.1x 0.8x
CGEN Unlock Forecast - 30 Days FREE Trial $134M x 2.7x
CGON Unlock Forecast - 30 Days FREE Trial $2529M x 3.8x
CGTX Unlock Forecast - 30 Days FREE Trial $170M -0.5x 24.1x
CHRO Unlock Forecast - 30 Days FREE Trial $8M x -2.0x
CHRS Unlock Forecast - 30 Days FREE Trial $150M 0.8x 1.3x
CLDI Unlock Forecast - 30 Days FREE Trial $5M -0.9x 3.1x
CMPX Unlock Forecast - 30 Days FREE Trial $483M -4.8x 5.2x
COEPW Unlock Forecast - 30 Days FREE Trial $M x x
CRBU Unlock Forecast - 30 Days FREE Trial $174M -1.5x 1.1x
CRDF Unlock Forecast - 30 Days FREE Trial $144M -4.0x 2.5x
CRGX Unlock Forecast - 30 Days FREE Trial $215M x 0.9x
CRIS Unlock Forecast - 30 Days FREE Trial $18M -0.3x -2.9x
CRSP Unlock Forecast - 30 Days FREE Trial $4579M -12.1x 2.7x
CSBR Unlock Forecast - 30 Days FREE Trial $111M -17.8x 20.4x
CVM Unlock Forecast - 30 Days FREE Trial $56M -0.9x 8.0x
CYTH Unlock Forecast - 30 Days FREE Trial $26M -0.6x -1.9x
CYTHW Unlock Forecast - 30 Days FREE Trial $7M x -0.5x
DBVT Unlock Forecast - 30 Days FREE Trial $1479M -3.3x 514.8x
DNA Unlock Forecast - 30 Days FREE Trial $568M -13.9x 0.3x
DNLI Unlock Forecast - 30 Days FREE Trial $2111M -8.7x 1.9x
DTIL Unlock Forecast - 30 Days FREE Trial $59M -2.2x 1.7x
DYAI Unlock Forecast - 30 Days FREE Trial $28M -7.3x 11.4x
EDIT Unlock Forecast - 30 Days FREE Trial $231M -0.8x 3.7x
ELEV Unlock Forecast - 30 Days FREE Trial $22M -1.0x 0.5x
ELUT Unlock Forecast - 30 Days FREE Trial $84M -1.4x -0.1x
ENGN Unlock Forecast - 30 Days FREE Trial $276M 3.7x 1.2x
ENGNW Unlock Forecast - 30 Days FREE Trial $37M x 0.1x
ENTX Unlock Forecast - 30 Days FREE Trial $94M 8.5x 5.4x
ENZ Unlock Forecast - 30 Days FREE Trial $25M -3.0x 0.5x
ENZB Unlock Forecast - 30 Days FREE Trial $37M x 0.8x
ESLA Unlock Forecast - 30 Days FREE Trial $39M -3.1x -16.9x
ESLAW Unlock Forecast - 30 Days FREE Trial $4M x 5.3x
EXEL Unlock Forecast - 30 Days FREE Trial $10793M 17.9x 5.3x
EXOZ Unlock Forecast - 30 Days FREE Trial $100M x 13.9x
FATE Unlock Forecast - 30 Days FREE Trial $115M -1.3x 0.4x
FDMT Unlock Forecast - 30 Days FREE Trial $406M -3.0x 1.0x
FENC Unlock Forecast - 30 Days FREE Trial $250M 1758.3x -39.7x
FNCH Unlock Forecast - 30 Days FREE Trial $20M -0.1x 1.4x
FTII Unlock Forecast - 30 Days FREE Trial $-26M x -0.7x
FTIIU Unlock Forecast - 30 Days FREE Trial $-26M x -0.8x
FTIIW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
GILD Unlock Forecast - 30 Days FREE Trial $148150M 23.5x 7.5x
GLUE Unlock Forecast - 30 Days FREE Trial $398M 16.5x 1.5x
GNTA Unlock Forecast - 30 Days FREE Trial $64M x 5.1x
GPLB Unlock Forecast - 30 Days FREE Trial $M x x
HALO Unlock Forecast - 30 Days FREE Trial $9509M 17.1x 28.6x
HLVX Unlock Forecast - 30 Days FREE Trial $105M -0.6x 0.7x
HUMA Unlock Forecast - 30 Days FREE Trial $224M -3.3x 55.2x
HUMAW Unlock Forecast - 30 Days FREE Trial $163M x -2.6x
IBRX Unlock Forecast - 30 Days FREE Trial $2427M -3.6x -4.1x
IKNA Unlock Forecast - 30 Days FREE Trial $61M -1.3x 0.5x
IKT Unlock Forecast - 30 Days FREE Trial $150M -1.0x 1.9x
IMCR Unlock Forecast - 30 Days FREE Trial $1831M x 4.7x
IMVT Unlock Forecast - 30 Days FREE Trial $2816M -14.5x 4.6x
INAB Unlock Forecast - 30 Days FREE Trial $21M -0.4x 2.4x
INBX Unlock Forecast - 30 Days FREE Trial $436M -6.8x 6.4x
INKT Unlock Forecast - 30 Days FREE Trial $59M -1.5x -1.4x
INMB Unlock Forecast - 30 Days FREE Trial $52M -2.5x 1.8x
INTS Unlock Forecast - 30 Days FREE Trial $7M -2.2x 3.4x
IOVA Unlock Forecast - 30 Days FREE Trial $851M -4.5x 1.2x
IPSC Unlock Forecast - 30 Days FREE Trial $44M -0.7x 0.2x
ITOS Unlock Forecast - 30 Days FREE Trial $393M -2.8x 0.7x
IVVD Unlock Forecast - 30 Days FREE Trial $137M -0.4x 3.2x
IZTC Unlock Forecast - 30 Days FREE Trial $99M x -27.5x
JSPR Unlock Forecast - 30 Days FREE Trial $44M -3.2x 1.9x
JSPRW Unlock Forecast - 30 Days FREE Trial $3M x 0.0x
KLRS Unlock Forecast - 30 Days FREE Trial $86M x 1.6x
KLTO Unlock Forecast - 30 Days FREE Trial $26M x 2.4x
KLTOW Unlock Forecast - 30 Days FREE Trial $1M x 0.4x
KOD Unlock Forecast - 30 Days FREE Trial $556M -2.5x 7.9x
KRBPQ Unlock Forecast - 30 Days FREE Trial $0M x x
KRYS Unlock Forecast - 30 Days FREE Trial $4099M 27.9x 3.9x
KYMR Unlock Forecast - 30 Days FREE Trial $3646M -17.8x 3.8x
KYTX Unlock Forecast - 30 Days FREE Trial $170M x 0.9x
LADX Unlock Forecast - 30 Days FREE Trial $M x x
LCTX Unlock Forecast - 30 Days FREE Trial $271M -4.7x 5.6x
LENZ Unlock Forecast - 30 Days FREE Trial $1163M -6.7x 5.6x
LIMN Unlock Forecast - 30 Days FREE Trial $0M x x
LXEO Unlock Forecast - 30 Days FREE Trial $271M -0.4x 2.0x
MAZE Unlock Forecast - 30 Days FREE Trial $696M x 2.7x
MGTX Unlock Forecast - 30 Days FREE Trial $693M -3.4x 20.9x
MGX Unlock Forecast - 30 Days FREE Trial $72M x 0.4x
MRNA Unlock Forecast - 30 Days FREE Trial $9457M -3.2x 1.0x
NBIX Unlock Forecast - 30 Days FREE Trial $14379M 41.3x 5.3x
NKGN Unlock Forecast - 30 Days FREE Trial $4M -0.1x -0.2x
NKGNW Unlock Forecast - 30 Days FREE Trial $1M x 0.0x
NMRA Unlock Forecast - 30 Days FREE Trial $271M -3.9x 1.5x
NVAX Unlock Forecast - 30 Days FREE Trial $1467M 3.5x 39.0x
OCGN Unlock Forecast - 30 Days FREE Trial $298M -4.3x 18.7x
OMGA Unlock Forecast - 30 Days FREE Trial $9M -0.7x 0.8x
OMGAQ Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
ONVO Unlock Forecast - 30 Days FREE Trial $35M -0.4x 95.9x
OTLK Unlock Forecast - 30 Days FREE Trial $73M -0.2x -2.3x
PALI Unlock Forecast - 30 Days FREE Trial $4M -0.2x 0.7x
PASG Unlock Forecast - 30 Days FREE Trial $23M -0.6x 0.6x
PCVX Unlock Forecast - 30 Days FREE Trial $4348M -20.4x 1.4x
PHGE Unlock Forecast - 30 Days FREE Trial $14M 1.5x 0.7x
PLUR Unlock Forecast - 30 Days FREE Trial $-4M -1.4x -9.1x
PLX Unlock Forecast - 30 Days FREE Trial $120M 19.1x 2.4x
PMCB Unlock Forecast - 30 Days FREE Trial $7M -2.6x 0.2x
PRME Unlock Forecast - 30 Days FREE Trial $500M -1.5x 8.2x
PROK Unlock Forecast - 30 Days FREE Trial $-80M x 0.0x
PSTX Unlock Forecast - 30 Days FREE Trial $926M -9.6x 10.6x
PTHS Unlock Forecast - 30 Days FREE Trial $M x x
QGEN Unlock Forecast - 30 Days FREE Trial $10339M x 2.9x
QNCX Unlock Forecast - 30 Days FREE Trial $86M -1.7x 7.4x
REPL Unlock Forecast - 30 Days FREE Trial $932M -3.8x 2.2x
RGEN Unlock Forecast - 30 Days FREE Trial $6531M 8219.1x 3.3x
RGNX Unlock Forecast - 30 Days FREE Trial $499M -1.8x 2.3x
RLAY Unlock Forecast - 30 Days FREE Trial $707M -2.0x 1.1x
RVMD Unlock Forecast - 30 Days FREE Trial $7134M -11.1x 3.4x
RVMDW Unlock Forecast - 30 Days FREE Trial $16M x 0.0x
RXRX Unlock Forecast - 30 Days FREE Trial $2110M -4.7x 2.3x
SABS Unlock Forecast - 30 Days FREE Trial $24M -2.3x 1.1x
SABSW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
SANA Unlock Forecast - 30 Days FREE Trial $809M -2.1x 6.6x
SCLX Unlock Forecast - 30 Days FREE Trial $62M -0.4x -0.3x
SCLXW Unlock Forecast - 30 Days FREE Trial $25M x -0.1x
SCNI Unlock Forecast - 30 Days FREE Trial $9674M -287.8x 1231.2x
SGMO Unlock Forecast - 30 Days FREE Trial $131M -1.6x 6.7x
SLDB Unlock Forecast - 30 Days FREE Trial $495M -0.9x 1.7x
SLXN Unlock Forecast - 30 Days FREE Trial $4M x 34.5x
SLXNW Unlock Forecast - 30 Days FREE Trial $866M x -189.1x
SNTI Unlock Forecast - 30 Days FREE Trial $51M -1.1x 1.3x
SRRK Unlock Forecast - 30 Days FREE Trial $4069M -18.5x 13.0x
SRZN Unlock Forecast - 30 Days FREE Trial $105M -0.5x 2.2x
SRZNW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
STRO Unlock Forecast - 30 Days FREE Trial $90M -1.0x -2.5x
SWTX Unlock Forecast - 30 Days FREE Trial $3539M -9.9x 8.5x
TARA Unlock Forecast - 30 Days FREE Trial $131M -2.1x 0.9x
TARS Unlock Forecast - 30 Days FREE Trial $2216M -12.4x 6.7x
TCBP Unlock Forecast - 30 Days FREE Trial $37M x 34.5x
TCBPW Unlock Forecast - 30 Days FREE Trial $1M x 1.0x
TCBPY Unlock Forecast - 30 Days FREE Trial $13M x 12.0x
TCRX Unlock Forecast - 30 Days FREE Trial $248M -4.6x 1.4x
TECH Unlock Forecast - 30 Days FREE Trial $8155M 75.2x 4.0x
TECX Unlock Forecast - 30 Days FREE Trial $314M -8.9x 1.1x
TIL Unlock Forecast - 30 Days FREE Trial $182M -1.1x 1.3x
TNYA Unlock Forecast - 30 Days FREE Trial $184M -2.5x 1.9x
TRML Unlock Forecast - 30 Days FREE Trial $688M -3.5x 2.7x
TSBX Unlock Forecast - 30 Days FREE Trial $8M -0.1x 0.6x
TSHA Unlock Forecast - 30 Days FREE Trial $919M -3.0x 3.7x
TTNP Unlock Forecast - 30 Days FREE Trial $8M -0.5x 4.5x
TVGN Unlock Forecast - 30 Days FREE Trial $168M x -29.3x
TVGNW Unlock Forecast - 30 Days FREE Trial $11M x -1.9x
TWST Unlock Forecast - 30 Days FREE Trial $1549M -12.6x 3.2x
VACH Unlock Forecast - 30 Days FREE Trial $-1436M x 0.0x
VACHU Unlock Forecast - 30 Days FREE Trial $-1585M x 0.0x
VCEL Unlock Forecast - 30 Days FREE Trial $1703M 239.6x 5.6x
VIGL Unlock Forecast - 30 Days FREE Trial $384M -1.1x 9.3x
VIR Unlock Forecast - 30 Days FREE Trial $732M -2.0x 0.8x
VIVS Unlock Forecast - 30 Days FREE Trial $3M x 0.3x
VOR Unlock Forecast - 30 Days FREE Trial $246M -0.6x 3.9x
VXRT Unlock Forecast - 30 Days FREE Trial $87M -0.9x 2.7x
VYGR Unlock Forecast - 30 Days FREE Trial $248M 570.6x 1.0x
WINT Unlock Forecast - 30 Days FREE Trial $18M -0.4x 4.2x
XFOR Unlock Forecast - 30 Days FREE Trial $8M 6.4x 0.4x
ZIVO Unlock Forecast - 30 Days FREE Trial $57M -31.3x -2.0x
ZURA Unlock Forecast - 30 Days FREE Trial $131M 5.0x 0.9x

Frequently Asked Questions - REGENXBIO Inc. Stock Forecast

How accurate are REGENXBIO Inc. stock predictions?

Our AI model demonstrates 49% historical accuracy for RGNX predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence REGENXBIO Inc. stock price forecasts?

Our analysis considers REGENXBIO Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is REGENXBIO Inc. a good investment in 2025?

Based on our AI analysis, REGENXBIO Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are REGENXBIO Inc. forecasts updated?

REGENXBIO Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced REGENXBIO Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for REGENXBIO Inc. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...